Products - Autoimmune - Gastroenterology -
Chronic inflammatory bowel disease (CIBD) is divided into two main variants; Ulcerative colitis (UC) and Crohn’s disease (CD). The highlight however is that both share an autoimmune etiology and have genetic predispositions.
Ulcerative Colitis
Ulcerative colitis manifests as bloody diarrhea with left lower quadrant pain. It mainly affects the rectum and goes as proximal as caecum, resulting in a continuous lesion. It causes mucosal and submucosal ulcers and depending upon the extent of the intestine involved, increases risk for colonic cancer.
Crohn’s disease
Crohn’s disease can affect the alimentary tract anywhere from the oral cavity all the way down to the anus. The striking feature is that it results in skip lesions, i.e., few segments are involved and few aren’t (not a continuous disease). Keep watch over bloody diarrhea and right lower quadrant pain which are the primary symptoms of Crohn’s disease.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.
wdt_ID | Method | Parameter | Substrate | Species/ Antigen |
---|---|---|---|---|
506 | IFA | antibodies against DNA-bound lactoferrin (pANCA) (LFS ab control) |
||
507 | IFA | DNA-bound lactoferrin (pANCA) ANCA negative |
LFS granulocytes HSS granulocytes (2 BIOCHIPs per field) |
HSS granulocytes (2 BIOCHIPs per field) human |
508 | EUROLINE | Autoimmune Gastrointestinal Diseases IgA (tissue transglutaminase (endomysium), gliadin-analogue fusion peptide (GAF-3X), mannan (ASCA)) |
EUROLINE | |
509 | EUROLINE | Autoimmune Gastrointestinal Diseases IgG (tissue transglutaminase (endomysium), gliadin-analogue fusion peptide (GAF-3X), parietal cell antigen (PCA) separately Intrinsic factor, mannan (ASCA)) |
EUROLINE | |
510 | IFA | intestinal goblet cells | intestinal tissue | monkey |
511 | IFA | antibodies against intestinal goblet cells (ulcerative colitis; UC IgA control) |
||
512 | IFA | antibodies against intestinal goblet cells (ulcerative colitis; UC IgG control) |
||
513 | IFA | intestinal goblet cells | goblet cells | EU 80 |
514 | IFA | antibodies against pancreas acini (CUZD1 control; associated with Crohn's disease) |
||
515 | IFA | Crohn's Disease Mosaic 1 pancreas antigen rPAg1 (CUZD1) pancreas antigen rPAg2 (GP2) |
3 BIOCHIPs per field: transfected cells transfected cells control transfection |
EU 90 EU 90 EU 90 |
516 | IFA | Crohn's Disease Mosaic 2 pancreas ag rPAg1(CUZD1) / rPAg2(GP2) |
2 BIOCHIPs per field: transfected cells control transfection |
EU 90 EU 90 |
517 | IFA | CIBD Screen 3 pancreas ag rPAg1(CUZD1) / rPAg2(GP2) intestinal goblet cells |
3 BIOCHIPs per field: transfected cells goblet cells control transfection |
EU 90 EU 80 EU 90 |
518 | IFA | CIBD Profile 3 upper row: pancreas ag rPAg1(CUZD1) / rPAg2(GP2) intestinal goblet cells pANCA DNA-bound lactoferrin (pANCA) ANCA negative bottom row: Saccharomyces cerevisiae |
transfected cells control transfection goblet cells granulocytes (EOH) LFS granulocytes HSS granulocytes fungal smear |
EU 90 EU 90 EU 80 human human human S. cerevisiae |
519 | IFA | CIBD Screen 6 pancreas ag rPAg1(CUZD1) / rPAg2(GP2) intestinal goblet cells Saccharomyces cerevisiae cANCA, pANCA, GS-ANA |
5 BIOCHIPs per field: transfected cells goblet cells fungal smear granulocytes (EOH) control transfection |
EU 90 EU 80 S. cerevisiae human EU 90 |
520 | IFA | CIBD Profile 7 upper row: pancreas ag rPAg1(CUZD1) / rPAg2(GP2) intestinal goblet cells pANCA bottom row: Saccharomyces cerevisiae |
transfected cells goblet cells granulocytes (EOH) control transfection fungal smear |
EU 90 EU 80 human EU 90 S. cerevisiae |
521 | IFA | antibodies against pancreas secretion (GP2 control; associated with Crohn's disease) |
||
522 | IFA | antibodies against Saccharomyces cerevisiae IgA positive control |
fungal smear |
Saccharomyces cerevisiae |
523 | IFA | antibodies against Saccharomyces cerevisiae IgG positive control |
fungal smear |
Saccharomyces cerevisiae |
524 | IFA | Saccharomyces cerevisiae | fungal smear |
Saccharomyces cerevisiae |
525 | IFA | Saccharomyces cerevisiae negative control |
||
526 | ELISA | Saccharomyces cerevisiae | antigen-coated microplate wells |
mannan of S. cerevisiae |
527 | ELISA | MabTrack level adalimumab | ||
528 | ELISA | MabTrack anti-drug antibody adalimumab | ||
529 | ELISA | MabTrack level infliximab | ||
530 | ELISA | MabTrack anti-drug antibody infliximab |
2023 EUROIMMUN US